Peripheral Vascular Stents - Medical Devices Pipeline Assessment, 2017 - Product Image

Peripheral Vascular Stents - Medical Devices Pipeline Assessment, 2017

  • ID: 4401997
  • Report
  • 246 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • 3D Biotek LLC
  • C. R. Bard Inc
  • Electroformed Stents Inc
  • LimFlow GmbH
  • Nipro Corp
  • Stron Medical
  • MORE
Peripheral Vascular Stents - Medical Devices Pipeline Assessment, 2017

Summary

The Medical Devices sector report, “Peripheral Vascular Stents - Medical Devices Pipeline Assessment, 2017" provides an overview of Peripheral Vascular Stents currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Peripheral Vascular Stents pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Peripheral Vascular Stents under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Peripheral Vascular Stents and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry
Reasons to buy
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Peripheral Vascular Stents under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3D Biotek LLC
  • C. R. Bard Inc
  • Electroformed Stents Inc
  • LimFlow GmbH
  • Nipro Corp
  • Stron Medical
  • MORE
1 Table of Contents
2 Introduction
2.1 Peripheral Vascular Stents Overview
3 Products under Development
3.1 Peripheral Vascular Stents - Pipeline Products by Stage of Development
3.2 Peripheral Vascular Stents - Pipeline Products by Segment
3.3 Peripheral Vascular Stents - Pipeline Products by Territory
3.4 Peripheral Vascular Stents - Pipeline Products by Regulatory Path
3.5 Peripheral Vascular Stents - Pipeline Products by Estimated Approval Date
3.6 Peripheral Vascular Stents - Ongoing Clinical Trials
4 Peripheral Vascular Stents - Pipeline Products under Development by Companies
4.1 Peripheral Vascular Stents Companies - Pipeline Products by Stage of Development
4.2 Peripheral Vascular Stents - Pipeline Products by Stage of Development
5 Peripheral Vascular Stents Companies and Product Overview
5.1 3D Biotek LLC Company Overview
5.2 480 Biomedical Inc Company Overview
5.3 Abbott Vascular Inc Company Overview
5.4 AndraTec GmbH Company Overview
5.5 Biotronik SE & Co KG Company Overview
5.6 Boston Scientific Corp Company Overview
5.7 C. R. Bard Inc Company Overview
5.8 Cardiatis SA Company Overview
5.9 Cook Medical Inc Company Overview
5.10 Cordis Corp Company Overview
5.11 Corinnova Inc Company Overview
5.12 Cytograft Tissue Engineering Inc (Inactive) Company Overview
5.13 Efferent Labs Inc Company Overview
5.14 Electroformed Stents Inc Company Overview
5.15 Elixir Medical Corp Company Overview
5.16 Hexacath SA Company Overview
5.17 InspireMD Inc Company Overview
5.18 Intact Vascular LLC Company Overview
5.19 iVascular SLU Company Overview
5.20 Lifetech Scientific (Shenzhen) Co Ltd Company Overview
5.21 LimFlow GmbH Company Overview
5.22 Medinol Ltd Company Overview
5.23 Micell Technologies Inc Company Overview
5.24 MicroVention Inc Company Overview
5.25 Natec Medical Ltd Company Overview
5.26 Nexeon MedSystems Inc Company Overview
5.27 Nipro Corp Company Overview
5.28 Northwestern University Company Overview
5.29 NSVascular, Inc. Company Overview
5.30 PeriTec Biosciences Ltd Company Overview
5.31 QualiMed Innovative Medizinprodukte GmbH Company Overview
5.32 Qvanteq AG Company Overview
5.33 REVA Medical Inc Company Overview
5.34 Stron Medical Company Overview
5.35 Synergy Flow Ltd Company Overview
5.36 Taewoong Medical Co Ltd Company Overview
5.37 Tepha Inc Company Overview
5.38 TissueGen Inc Company Overview
5.39 University of Michigan Company Overview
5.40 University of Pittsburgh Medical Center Company Overview
5.41 Vascular Bioresorbable Technologies Company Overview
5.42 Vascular Concepts Ltd Company Overview
5.43 Vascular Dynamics Ltd. Company Overview
5.44 Veniti Inc Company Overview
5.45 Veryan Medical Ltd Company Overview
5.46 VueKlar Cardiovascular Ltd Company Overview
5.47 Wake Forest University Health Sciences Company Overview
5.48 Xenogenics Corporation Company Overview
6 Peripheral Vascular Stents- Recent Developments
6.1 Sep 07, 2017: Abbott Named Industry Leader for Responsible and Sustainable Business for Five Consecutive Years on the Dow Jones Sustainability Index
6.2 Sep 01, 2017: Data Published in The Lancet Shows Positive Results at Primary Endpoint in the Treatment of Resistant Hypertension with MobiusHD Device
6.3 Aug 29, 2017: Abbott Issues New Updates for Implanted Cardiac Devices
6.4 Aug 28, 2017: Interim Data on MobiusHD Presented at the European Society of Cardiology Shows Promise in the Treatment of Resistant Hypertension
6.5 Aug 22, 2017: Vascular Dynamics, a Part of the Rainbow Medical Investment Cluster, Received FDA Approval to Begin Conclusive and Pivotal Trial Experimentation for Their Flagship Product Designed to Treat Chronic Hypertension
6.6 Aug 22, 2017: Getinge announces full U.S. availability of Pulsar-18 self-expanding stent from BIOTRONIK for patients with peripheral artery disease
6.7 Aug 22, 2017: Medtronic Reports First Quarter Financial Results
6.8 Aug 15, 2017: Vascular Dynamics Announces FDA Approval to Initiate CALM 2 Trial for MobiusHD System for the Treatment of Resistant Hypertension
6.9 Aug 10, 2017: Neovasc Announces Results for the Second Quarter of 2017
6.10 Aug 08, 2017: Inspire Reports Double Digit Sequential and Year-Over-Year Revenue Growth for the Second Quarter of 2017
6.11 Aug 08, 2017: InspireMD Reports Double Digit Sequential and Year-Over-Year Revenue Growth for the Second Quarter of 2017
6.12 Aug 01, 2017: LimFlow Announces Publication of Positive Results from Pilot Study of LimFlow Percutaneous Deep Vein Arterialization (pDVA) System
6.13 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017
6.14 Jul 26, 2017: Merit Medical Reports Record Revenue and Non-GAAP Net Income for Second Quarter 2017, Raises 2017 Guidance and Gives Preliminary 2018-2019 Guidance
6.15 Jul 26, 2017: CONMED Announces Second Quarter 2017 Financial Results
6.16 Jul 20, 2017: Abbott Reports Second-Quarter 2017 Results
6.17 Jul 18, 2017: Intact Vascular Announces Enrollment of First European Patient in Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK) Clinical Trial with the Tack Endovascular System
6.18 Jul 18, 2017: AngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results
6.19 Jul 12, 2017: STENTYS: Revenues Of €1.7 Million in the Second Quarter Of 2017
6.20 Jul 11, 2017: LimFlow Announces First Patient Treated in U.S. Feasibility Study and Commencement of International Post-Market Study
6.21 Jul 10, 2017: FDA Approves 6-Month Primary Endpoint for the Tack Endovascular System in Below the Knee Disease
6.22 Jul 03, 2017: BIOTRONIK US Announces Pivotal Trial Results of the Pulsar-18 Stent with 4-French Delivery System
6.23 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day
6.24 Jun 06, 2017: LimFlow Expands Senior Management Team and Opens Silicon Valley Office
6.25 Jun 02, 2017: InspireMD Announces Appointment of Paul Stuka as Chairman of the Board
6.26 May 26, 2017: Merit Medical Announces Appointment of New Director
6.27 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results
6.28 May 15, 2017: Elixir Medical To Present Data on PRAVA Bioresorbable scaffold system at EuroPCR 2017
6.29 May 10, 2017: Neovasc Announces Results for the First Quarter of 2017
6.30 Apr 27, 2017: New Data Show Efficacy of Pulsar-18 Bare Metal Stent; Combination with Passeo-18 Lux DCB Challenges Results with Drug-Eluting Stents
6.31 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017
6.32 Apr 27, 2017: Merit Medical Reports Results for First Quarter of 2017
6.33 Apr 26, 2017: LimFlow Receives FDA Approval for U.S. Feasibility Study of Minimally-Invasive Technology Designed to Restore Perfusion in “No Option” Critical Limb Ischemia Patients
6.34 Apr 26, 2017: CONMED Announces First Quarter 2017 Financial Results
6.35 Apr 25, 2017: Edwards Lifesciences Reports First Quarter Results
6.36 Apr 24, 2017: STENTYS Reports a 22% Increase in Revenues in the First Quarter of 2017
6.37 Apr 23, 2017: Bard Announces First Quarter Results
6.38 Apr 21, 2017: Getinge launches the new Advanta V12 - 32mm Balloon Expandable Covered Stent
6.39 Apr 20, 2017: Lombard Medical Appoints New CEO
6.40 Apr 19, 2017: Abbott Reports First-Quarter 2017 Results
6.41 Apr 03, 2017: iVascular Receives CE Mark Approval for iVolution 200mm SX stent
6.42 Apr 03, 2017: STENTYS is Strengthening Its Board by Co-Opting Two New Independent Members
6.43 Mar 30, 2017: AngioDynamics Reports Fiscal 2017 Third Quarter Results
6.44 Mar 24, 2017: LifeTech Announces 2016 Annual Results
6.45 Mar 23, 2017: Intact Vascular Announces Completion Of Enrollment In The Tack Optimized Balloon Angioplasty II (Toba II) Clinical Trial
6.46 Mar 23, 2017: Neovasc Announces Results for the Fourth Quarter and Fiscal Year 2016
6.47 Mar 13, 2017: Cook Medical Announces Umesh Patel as President of Cook Biotech
6.48 Mar 10, 2017: Neovasc Announces TSX Symbol Change to NVCN
6.49 Mar 07, 2017: Anteo Technologies Announces Verification Study With Cook Medical Australia
6.50 Mar 06, 2017: GORE TIGRIS Vascular Stent Gains Health Canada Approval for Treatment of Peripheral Artery Disease
6.51 Mar 02, 2017: North Dallas Research Associates and Cardiac Center of Texas Begin Enrollment in TOBA II BTK Clinical Trial for New Peripheral Revascularization Treatment Option
6.52 Feb 27, 2017: TissueGen appoints new scientific advisory board member
6.53 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results
6.54 Feb 21, 2017: Merit Medical Reports Results for Fourth Quarter and Year Ended December 31, 2016
6.55 Feb 16, 2017: Medinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US
6.56 Feb 16, 2017: InspireMD Provides Year End Business Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
6.57 Feb 13, 2017: Intact Vascular's Tack Optimized Balloon Angioplasty II Below The Knee (TOBA II BTK) Clinical Trial Commences Enrollment With First Implant Of The Tack Endovascular System
6.58 Feb 09, 2017: Terumo Announces Change of Executive Officers
6.59 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors
6.60 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016
6.61 Feb 01, 2017: Vascular Dynamics' Announces Expedited Access Pathway Designation by FDA for MobiusHD to Accelerate US Access for Treatment of Resistant Hypertension
6.62 Feb 01, 2017: CONMED Announces Fourth Quarter and Fiscal Year 2016 Financial Results
6.63 Feb 01, 2017: Edwards Lifesciences Reports Fourth Quarter Results
6.64 Jan 31, 2017: Terumo Opens a Branch in Yangon
6.65 Jan 30, 2017: FDA Approves First Balloon Expandable Stent Graft For Use In The Iliac Artery
6.66 Jan 26, 2017: Bard Announces Fourth Quarter Results
6.67 Jan 18, 2017: Neovasc Announces Update in Litigation with CardiAQ
6.68 Jan 17, 2017: Intact Vascular’s Tack Endovascular System Secures CE Mark for Repair of Dissections Following Angioplasty Below the Knee
6.69 Jan 12, 2017: STENTYS: 2016 Annual Revenues up 20% at €7.3 Million
6.70 Jan 06, 2017: AngioDynamics Reports Fiscal 2017 Second Quarter Results
6.71 Dec 12, 2016: Terumo Formulates 5-Year Mid- to Long-term Growth Strategy
6.72 Dec 08, 2016: Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
6.73 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results
6.74 Nov 21, 2016: VEITHsymposium 2016: BIOTRONIK Showcases Positive Results for Pulsar-18 Stent in the SFA
6.75 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report
6.76 Nov 15, 2016: Final Patient Enrolled for Iliofemoral Venous Stent Study
6.77 Nov 15, 2016: LimFlow Receives CE Mark for Purely Percutaneous Critical Limb Ischemia Technology Designed to Restore Perfusion for “No Option” Patients
6.78 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction
6.79 Nov 14, 2016: InspireMD Reports Financial Results for the Third Quarter Ended September 30, 2016
6.80 Nov 14, 2016: Neovasc Reports Third Quarter Results for 2016
6.81 Nov 09, 2016: AngioDynamics Announces Addition of New Board Members
6.82 Oct 31, 2016: FDA Approves TOBA II BTK Pivotal IDE Clinical Study
6.83 Oct 27, 2016: CONMED Announces Third Quarter 2016 Financial Results
6.84 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016
6.85 Oct 26, 2016: Merit Medical Reports Sales Up 15.3% for the Quarter Ended September 30, 2016
6.86 Oct 25, 2016: Edwards Lifesciences Reports Third Quarter Results
6.87 Oct 25, 2016: Bard Announces Third Quarter Results
6.88 Oct 24, 2016: Boston Scientific announced key Presentations on Eluvia Drug-Eluting Vascular Stent System at Transcatheter Cardiovascular Therapeutics 2016
6.89 Oct 20, 2016: Akesys Medical and Elixir Medical Announce First Human Implant of the PRAVA Bioresorbable Scaffold for Peripheral Vascular Disease
6.90 Oct 19, 2016: Abbott Reports Third-Quarter 2016 Results
6.91 Oct 18, 2016: LimFlow Names Daniel Rose as Chief Executive Officer
6.92 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer
6.93 Oct 05, 2016: AngioDynamics Reports Fiscal 2017 First Quarter Results
6.94 Sep 30, 2016: Pitt Team Receives $2.5 million in DOD Funds for First Retrievable Vascular Stent
6.95 Sep 30, 2016: Pitt Team Receives $2.5 million in DOD Funds for First Retrievable Vascular Stent
7 Appendix
7.1 Methodology
7.2 About
7.3 Contact
7.4 Disclaimer

List of Tables
Table 1: Peripheral Vascular Stents - Pipeline Products by Stage of Development
Table 2: Peripheral Vascular Stents - Pipeline Products by Segment
Table 3: Peripheral Vascular Stents - Pipeline Products by Territory
Table 4: Peripheral Vascular Stents - Pipeline Products by Regulatory Path
Table 5: Peripheral Vascular Stents - Pipeline Products by Estimated Approval Date
Table 6: Peripheral Vascular Stents - Ongoing Clinical Trials
Table 7: Peripheral Vascular Stents Companies - Pipeline Products by Stage of Development
Table 8: Peripheral Vascular Stents - Pipeline Products by Stage of Development
Table 9: 3D Biotek LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 10: Bioresorbable Drug Eluting Peripheral Polymer Stent - Product Status
Table 11: Bioresorbable Drug Eluting Peripheral Polymer Stent - Product Description
Table 12: 480 Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 13: Stanza Bioresorbable Pediatric Scaffold - Product Status
Table 14: Stanza Bioresorbable Pediatric Scaffold - Product Description
Table 15: Stanza Bioresorbable Self-Expanding Scaffold - Product Status
Table 16: Stanza Bioresorbable Self-Expanding Scaffold - Product Description
Table 17: 480 Biomedical Inc - Ongoing Clinical Trials Overview
Table 18: Stanza Bioresorbable Self-Expanding Scaffold - An Evaluation of the 480 Biomedical STANZA Drug-Eluting Resorbable Scaffold (DRS) System in the Treatment of de Novo SFA Lesions
Table 19: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 20: ESPRIT Bioresorbable Vascular Scaffold - Product Status
Table 21: ESPRIT Bioresorbable Vascular Scaffold - Product Description
Table 22: Abbott Vascular Inc - Ongoing Clinical Trials Overview
Table 23: ESPRIT Bioresorbable Vascular Scaffold - Observational Study of Treatment of Bioresorbable Vascular Scaffolds Restenosis
Table 24: ESPRIT Bioresorbable Vascular Scaffold - Safety and Feasibility of Bioabsorbable Everolimus-Eluting Stents for Patients with Internal Pudendal Artery-related Arteriogenic Erectile Dysfunction (PERFECT-ABSORB)
Table 25: AndraTec GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 26: Pillar Bifurcation Reconstruction Device - Product Status
Table 27: Pillar Bifurcation Reconstruction Device - Product Description
Table 28: Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
Table 29: Astron Pulsar Self Expanding Peripheral Stent - Product Status
Table 30: Astron Pulsar Self Expanding Peripheral Stent - Product Description
Table 31: Biotronik SE & Co KG - Ongoing Clinical Trials Overview
Table 32: Astron Pulsar Self Expanding Peripheral Stent - BIOTRONIK - The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar-18 Stents: BIOFLEX-I Europe
Table 33: Astron Pulsar Self Expanding Peripheral Stent - Self-expanding Nitinol Stents of High Versus Low Chronic Outward Force in De-novo Femoropopliteal Occlusive Arterial Lesions
Table 34: Astron Pulsar Self Expanding Peripheral Stent - The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Table 35: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 36: Eluvia Drug-Eluting Vascular Stent System - Product Status
Table 37: Eluvia Drug-Eluting Vascular Stent System - Product Description
Table 38: Gallbladder Drainage System - Product Status
Table 39: Gallbladder Drainage System - Product Description
Table 40: Wallstent RP Endoprosthesis - Venous Outflow Obstruction - Product Status
Table 41: Wallstent RP Endoprosthesis - Venous Outflow Obstruction - Product Description
Table 42: Boston Scientific Corp - Ongoing Clinical Trials Overview
Table 43: Eluvia Drug-Eluting Vascular Stent System - A Randomized Trial Comparing the ELUVIA Drug-eluting Stent Versus Bare Metal Self-expanding Nitinol Stents in the Treatment of Superficial Femoral and/or Proximal Popliteal Arteries
Table 44: Eluvia Drug-Eluting Vascular Stent System - A Randomized Trial Comparing the ELUVIA Drug-eluting Stent Versus Zilver PTX Stent for Treatment of Superficial Femoral and/or Proximal Popliteal Arteries
Table 45: Eluvia Drug-Eluting Vascular Stent System - A Real World Evaluation of the ELUVIA Drug Eluting Stent in All-comers with Superficial Femoral Artery and Proximal Popliteal Artery Disease
Table 46: Wallstent RP Endoprosthesis - Venous Outflow Obstruction - Sinai Vein Stent Registry
Table 47: C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 48: Bard LifeStent 5F Vascular Stent System - Product Status
Table 49: Bard LifeStent 5F Vascular Stent System - Product Description
Table 50: VENOVO Venous Stent - Product Status
Table 51: VENOVO Venous Stent - Product Description
Table 52: C. R. Bard Inc - Ongoing Clinical Trials Overview
Table 53: Bard LifeStent 5F Vascular Stent System - A Prospective Study of the Performance of the Bard Lifestent 5F Vascular Stent System
Table 54: Cardiatis SA Pipeline Products & Ongoing Clinical Trials Overview
Table 55: Cardiatis FluidSmart 3D Stent - Product Status
Table 56: Cardiatis FluidSmart 3D Stent - Product Description
Table 57: Cook Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 58: Evolution Biliary Stent System-Partially Covered - Product Status
Table 59: Evolution Biliary Stent System-Partially Covered - Product Description
Table 60: Evolution Esophageal Stent System-Fully Covered - Product Status
Table 61: Evolution Esophageal Stent System-Fully Covered - Product Description
Table 62: Zenith Connection Endovascular Covered Stent - Product Status
Table 63: Zenith Connection Endovascular Covered Stent - Product Description
Table 64: ZILVER PTX Drug Eluting Peripheral Stent - Product Status
Table 65: ZILVER PTX Drug Eluting Peripheral Stent - Product Description
Table 66: Zilver Vena Venous Self-Expanding Stent - Product Status
Table 67: Zilver Vena Venous Self-Expanding Stent - Product Description
Table 68: Cook Medical Inc - Ongoing Clinical Trials Overview
Table 69: ZILVER PTX Drug Eluting Peripheral Stent - A Randomized Trial Comparing the ELUVIA Drug-eluting Stent Versus Zilver PTX Stent for Treatment of Superficial Femoral and/or Proximal Popliteal Arteries
Table 70: ZILVER PTX Drug Eluting Peripheral Stent - Bare Metal Stent Versus Paclitaxel Eluting Stent in the Setting of Primary Stenting of Intermediate Length Femoropopliteal Lesions
Table 71: ZILVER PTX Drug Eluting Peripheral Stent - Comparison of the Primary Long Versus Short Coverage with Drug-Eluting Stents for Long Femoropopliteal Artery Disease (PARADE II): Investigator-initiated Clinical Study
Table 72: ZILVER PTX Drug Eluting Peripheral Stent - Drug Eluting Stent for the Management of Peripheral Arterial Disease of the SFA (DESPERADO-SFA Study)
Table 73: ZILVER PTX Drug Eluting Peripheral Stent - Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses
Table 74: ZILVER PTX Drug Eluting Peripheral Stent - The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment the Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions (ZILVERPASS)
Table 75: ZILVER PTX Drug Eluting Peripheral Stent - Zilver PTX Drug-eluting Peripheral Stent Post-approval Study
Table 76: ZILVER PTX Drug Eluting Peripheral Stent - Zilver PTX Post-market Surveillance Study of Paclitaxel-eluting Stents for Treating Femoropopliteal Artery Disease in Japan
Table 77: Zilver Vena Venous Self-Expanding Stent - Evaluation of the Zilver Vena Venous Stent in the Treatment of Symptomatic Iliofemoral Venous Outflow Obstruction
Table 78: Evolution Esophageal Stent System-Fully Covered - Clinical Investigation to Evaluate Removal of the Evolution Esophageal Stent - Fully Covered
Table 79: Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 80: FlexStent Femoropopliteal Self Expanding Stent System - SFA - Product Status
Table 81: FlexStent Femoropopliteal Self Expanding Stent System - SFA - Product Description
Table 82: FlexStent Self Expanding Below-The-Knee Venous Stent System - Product Status
Table 83: FlexStent Self Expanding Below-The-Knee Venous Stent System - Product Description
Table 84: FlexStent Self Expanding Venous Stent System - Product Status
Table 85: FlexStent Self Expanding Venous Stent System - Product Description
Table 86: Tibial SE FlexStent - Product Status
Table 87: Tibial SE FlexStent - Product Description
Table 88: Cordis Corp - Ongoing Clinical Trials Overview
Table 89: FlexStent Femoropopliteal Self Expanding Stent System - SFA - Evaluation of Safety and Efficacy of the FlexStent Femoropopliteal Self-expanding Stent System Study
Table 90: Corinnova Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 91: Hybrid Dynamic Stent - Product Status
Table 92: Hybrid Dynamic Stent - Product Description
Table 93: Cytograft Tissue Engineering Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 94: LifeJacket Stent Graft - Peripheral - Product Status
Table 95: LifeJacket Stent Graft - Peripheral - Product Description
Table 96: Efferent Labs Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 97: RTI-LICD Plexisense - Product Status
Table 98: RTI-LICD Plexisense - Product Description
Table 99: Electroformed Stents Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 100: Helical Stent - Product Status
Table 101: Helical Stent - Product Description
Table 102: Patch Stent - Product Status
Table 103: Patch Stent - Product Description
Table 104: Pleated Stent - Product Status
Table 105: Pleated Stent - Product Description
Table 106: Elixir Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 107: PRAVA Bioresorbable Scaffold - Product Status
Table 108: PRAVA Bioresorbable Scaffold - Product Description
Table 109: Elixir Medical Corp - Ongoing Clinical Trials Overview
Table 110: PRAVA Bioresorbable Scaffold - Drug Eluting Scaffold with an Absorbable Platform for Primary Lower Extremity Arterial Revascularization: DESappear Study
Table 111: Hexacath SA Pipeline Products & Ongoing Clinical Trials Overview
Table 112: HELIOS LD Peripheral Balloon Expandable Bio Active Stent - Product Status
Table 113: HELIOS LD Peripheral Balloon Expandable Bio Active Stent - Product Description
Table 114: InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 115: PVGuard Peripheral - Product Status
Table 116: PVGuard Peripheral - Product Description
Table 117: Intact Vascular LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 118: Tack Endovascular System - ATK - Product Status
Table 119: Tack Endovascular System - ATK - Product Description
Table 120: Tack Endovascular System - BTK - Product Status
Table 121: Tack Endovascular System - BTK - Product Description
Table 122: Intact Vascular LLC - Ongoing Clinical Trials Overview
Table 123: Tack Endovascular System - ATK - Tack Optimized Balloon Angioplasty (TOBA) Study for Femoropopliteal Arteries Using the Tack-IT Endovascular Stapler
Table 124: Tack Endovascular System - ATK - Tack Optimized Balloon Angioplasty Study for Superficial Femoral and Proximal Popliteal Arteries Using the Tack Endovascular System
Table 125: Tack Endovascular System - ATK - Tack Optimized Drug Coated Balloon Angioplasty in the Superficial Femoral and Proximal Popliteal Arteries Using the Tack Endovascular System
Table 126: Tack Endovascular System - BTK - Tack Optimized Balloon Angioplasty Study for the below the Knee Arteries Using the Tack Endovascular System
Table 127: iVascular SLU Pipeline Products & Ongoing Clinical Trials Overview
Table 128: Angiolite - BTK - Product Status
Table 129: Angiolite - BTK - Product Description
Table 130: Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 131: Peripheral Bare Stent - Product Status
Table 132: Peripheral Bare Stent - Product Description
Table 133: Peripheral Cover Stent - Product Status
Table 134: Peripheral Cover Stent - Product Description
Table 135: LimFlow GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 136: LimFlow Percutaneous Deep Vein Arterialisation System - Product Status
Table 137: LimFlow Percutaneous Deep Vein Arterialisation System - Product Description
Table 138: LimFlow GmbH - Ongoing Clinical Trials Overview

List of Figures
Figure 1: Peripheral Vascular Stents - Pipeline Products by Stage of Development
Figure 2: Peripheral Vascular Stents - Pipeline Products by Segment
Figure 3: Peripheral Vascular Stents - Pipeline Products by Territory
Figure 4: Peripheral Vascular Stents - Pipeline Products by Regulatory Path
Figure 5: Peripheral Vascular Stents - Pipeline Products by Estimated Approval Date
Figure 6: Peripheral Vascular Stents - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 3D Biotek LLC
  • 480 Biomedical Inc
  • Abbott Vascular Inc
  • AndraTec GmbH
  • Biotronik SE & Co KG
  • Boston Scientific Corp
  • C. R. Bard Inc
  • Cardiatis SA
  • Cook Medical Inc
  • Cordis Corp
  • Corinnova Inc
  • Cytograft Tissue Engineering Inc
  • Efferent Labs Inc
  • Electroformed Stents Inc
  • Elixir Medical Corp
  • Hexacath SA
  • InspireMD Inc
  • Intact Vascular LLC
  • iVascular SLU
  • Lifetech Scientific (Shenzhen) Co Ltd
  • LimFlow GmbH
  • Medinol Ltd
  • Micell Technologies Inc
  • MicroVention Inc
  • Natec Medical Ltd
  • Nexeon MedSystems Inc
  • Nipro Corp
  • Northwestern University
  • NSVascular, Inc.
  • PeriTec Biosciences Ltd
  • QualiMed Innovative Medizinprodukte GmbH
  • Qvanteq AG
  • REVA Medical Inc
  • Stron Medical
  • Synergy Flow Ltd
  • Taewoong Medical Co Ltd
  • Tepha Inc
  • TissueGen Inc
  • University of Michigan
  • University of Pittsburgh Medical Center
  • Vascular Bioresorbable Technologies
  • Vascular Concepts Ltd
  • Vascular Dynamics Ltd.
  • Veniti Inc
  • Veryan Medical Ltd
  • VueKlar Cardiovascular Ltd
  • Wake Forest University Health Sciences
  • Xenogenics Corporation
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll